Alterity Therapeutics Limited Stock Net Income
| PRNAF Stock | USD 0.01 0.00 0.00% |
As of the 12th of February 2026, Alterity Therapeutics shows the Standard Deviation of 9.3, mean deviation of 2.43, and Risk Adjusted Performance of 0.0779. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Alterity Therapeutics, as well as the relationship between them. Please confirm Alterity Therapeutics standard deviation, as well as the relationship between the treynor ratio and kurtosis to decide if Alterity Therapeutics is priced correctly, providing market reflects its regular price of 0.0097 per share. As Alterity Therapeutics appears to be a penny stock we also recommend to validate its information ratio numbers.
Alterity Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Alterity Therapeutics' valuation are provided below:Alterity Therapeutics Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Alterity |
Alterity Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Alterity Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Alterity Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Alterity Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Alterity Therapeutics Limited or generate 0.0% return on investment in Alterity Therapeutics over 90 days. Alterity Therapeutics is related to or competes with Biostem Technologies, Imugene, Starpharma Holdings, Helix BioPharma, and Satellos Bioscience. Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimers disease, ... More
Alterity Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Alterity Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Alterity Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.0756 | |||
| Maximum Drawdown | 81.61 |
Alterity Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Alterity Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Alterity Therapeutics' standard deviation. In reality, there are many statistical measures that can use Alterity Therapeutics historical prices to predict the future Alterity Therapeutics' volatility.| Risk Adjusted Performance | 0.0779 | |||
| Jensen Alpha | 0.7275 | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | 1.09 |
Alterity Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0779 | |||
| Market Risk Adjusted Performance | 1.1 | |||
| Mean Deviation | 2.43 | |||
| Coefficient Of Variation | 1153.46 | |||
| Standard Deviation | 9.3 | |||
| Variance | 86.44 | |||
| Information Ratio | 0.0756 | |||
| Jensen Alpha | 0.7275 | |||
| Total Risk Alpha | (0.30) | |||
| Treynor Ratio | 1.09 | |||
| Maximum Drawdown | 81.61 | |||
| Skewness | 6.8 | |||
| Kurtosis | 53.4 |
Alterity Therapeutics Backtested Returns
Alterity Therapeutics appears to be out of control, given 3 months investment horizon. Alterity Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0909, which signifies that the company had a 0.0909 % return per unit of risk over the last 3 months. By analyzing Alterity Therapeutics' technical indicators, you can evaluate if the expected return of 0.89% is justified by implied risk. Please makes use of Alterity Therapeutics' Mean Deviation of 2.43, risk adjusted performance of 0.0779, and Standard Deviation of 9.3 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Alterity Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 0.73, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Alterity Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Alterity Therapeutics is expected to be smaller as well. Please check Alterity Therapeutics' standard deviation and the relationship between the treynor ratio and day typical price , to make a quick decision on whether Alterity Therapeutics' price patterns will revert.
Auto-correlation | -0.14 |
Insignificant reverse predictability
Alterity Therapeutics Limited has insignificant reverse predictability. Overlapping area represents the amount of predictability between Alterity Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Alterity Therapeutics price movement. The serial correlation of -0.14 indicates that less than 14.0% of current Alterity Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.14 | |
| Spearman Rank Test | 0.76 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Alterity Therapeutics Limited reported net income of (12.85 Million). This is 103.76% lower than that of the Healthcare sector and 118.34% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.25% higher than that of the company.
Alterity Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in net income category among its peers.
Alterity Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Shares Owned By Insiders | 15.14 % | |||
| Shares Owned By Institutions | 0.33 % | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 3.12 X | |||
| Gross Profit | 4.76 M | |||
| EBITDA | (15.08 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 34.81 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 117.49 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 7.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (12.34 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.87 | |||
| Market Capitalization | 18.77 M | |||
| Total Asset | 41.36 M | |||
| Retained Earnings | (125 M) | |||
| Working Capital | 32 M | |||
| Current Asset | 34 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 91.2 | |||
| Net Asset | 41.36 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Alterity Pink Sheet
Alterity Therapeutics financial ratios help investors to determine whether Alterity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterity with respect to the benefits of owning Alterity Therapeutics security.